Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Evoke Pharma is a drug manufacturers-specialty & generic business based in the US. Evoke Pharma shares (EVOK) are listed on the NASDAQ and all prices are listed in US Dollars. Evoke Pharma employs 4 staff and has a trailing 12-month revenue of around $2.1 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $2.83 |
|---|---|
| 52-week range | $1.37 - $10.54 |
| 50-day moving average | $3.45 |
| 200-day moving average | $2.63 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.26 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.83 from 2023-03-17
| 1 week (2023-03-13) | -20.95% |
|---|---|
| 1 month (2023-02-17) | 2.83 |
| 3 months (2022-12-20) | 36.39% |
| 6 months (2022-09-20) | 33.49% |
| 1 year (2022-03-18) | 424.07% |
|---|---|
| 2 years (2021-03-19) | 24.67% |
| 3 years (2020-03-20) | 215.92% |
| 5 years (2018-03-19) | 24.72 |
| Revenue TTM | $2.1 million |
|---|---|
| Gross profit TTM | $1.3 million |
| Return on assets TTM | -38.03% |
| Return on equity TTM | -157.06% |
| Profit margin | 0% |
| Book value | $1.66 |
| Market capitalisation | $11 million |
TTM: trailing 12 months
We're not expecting Evoke Pharma to pay a dividend over the next 12 months.
Evoke Pharma's shares were split on a 1:12 basis on 22 May 2022. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Evoke Pharma shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Evoke Pharma shares which in turn could have impacted Evoke Pharma's share price.
Over the last 12 months, Evoke Pharma's shares have ranged in value from as little as $1.372 up to $10.536. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evoke Pharma's is 0.4023. This would suggest that Evoke Pharma's shares are less volatile than average (for this exchange).
Evoke Pharma, Inc. , a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California. .
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.